- Supported exchanges /
- F /
- 8ZD.F
ABBISKO CAYMAN DL-00001 (8ZD F) stock market data APIs
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
ABBISKO CAYMAN DL-00001 Financial Data Overview
| 0.448 | |
| 0.436 | |
| - | |
| 0.448 | |
| 0.436 | |
| 0.236-0.52 | |
| 322 M | |
| 625 M | |
| 497 M | |
| 1.431 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ABBISKO CAYMAN DL-00001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 497 M
- EBITDA -30 353 000
- Earnings Per Share 0
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ABBISKO CAYMAN DL-00001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ABBISKO CAYMAN DL-00001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
